BRCA1 and breast cancer: In this cohort study of BCT in pathogenic BRCA1/2 variant carriers, we found that women with breast cancer and pathogenic variants in BRCA1/2 treated with BCT have quantifiable above-average risks of ipsilateral and contralateral breast cancer events.